Structure Therapeutics reports positive early trial data for two oral obesity drug candidates
Structure Therapeutics reported topline results from a Phase 1/2a single-dose study of ACCG-2671, an oral amylin receptor agonist, and 72-week results from an open-label extension of its Phase 2b aleniglipron trial. The filing shows aleniglipron participants reached up to 16.2% body weight loss, while ACCG-2671 showed a half-life of about 6 days but dose-related nausea and vomiting at the 5 mg and 10 mg doses.
Key points
- Aleniglipron 72-week open-label extension: up to 16.2% mean body weight loss at the 180 mg dose, with fewer than 5% of participants discontinuing due to treatment-emergent adverse events
- ACCG-2671 single ascending dose study (31 healthy participants): terminal half-life of about 6 days; nausea in 4 of 5 at 5 mg and in 6 of 6 at 10 mg
- ACCG-2671 multiple ascending dose portion has begun, with topline data expected in the first half of 2027
- Phase 3 ACCOMPLISH program for aleniglipron is enrolling, with topline data expected in the second half of 2028
The filing
Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.